{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:01:47Z","timestamp":1760144507122,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.cjca.2010.12.021","type":"journal-article","created":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T19:50:11Z","timestamp":1301687411000},"page":"222-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Jersey","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Schneider","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Rinfret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Jaime","family":"Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wissam","family":"El-Hadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Topol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2010.12.021_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2010.12.021_bib3","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2010.12.021_bib4","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2010.12.021_bib5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2010.12.021_bib6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib7","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib8","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2010.12.021_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1524-4733.2009.00529.x","article-title":"Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial","volume":"12","author":"Chen","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.cjca.2010.12.021_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ahj.2004.03.028","article-title":"Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial","volume":"148","author":"Bhatt","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2010.12.021_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ahj.2005.03.017","article-title":"A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial","volume":"150","author":"Bhatt","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2010.12.021_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2005.03.073","article-title":"Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"46","author":"Beinart","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2010.12.021_bib14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jama.288.15.1851","article-title":"Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction","volume":"288","author":"Mahoney","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2010.12.021_bib15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2004.11.051","article-title":"Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation","volume":"45","author":"Weintraub","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2010.12.021_bib16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2010.12.021_bib17","first-page":"175","article-title":"Saskatchewan Health's linkable data bases and pharmacoepidemiology","volume":"6","author":"Malcolm","year":"1993","journal-title":"Post Marketing Surveillance"},{"year":"2000","series-title":"Health databases in Saskatchewan","author":"Downey","key":"10.1016\/j.cjca.2010.12.021_bib18"},{"key":"10.1016\/j.cjca.2010.12.021_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1524-4733.2004.75013.x","article-title":"Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis","volume":"7","author":"Caro","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.cjca.2010.12.021_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1191\/0962280202sm304ra","article-title":"Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods","volume":"11","author":"O'Brien","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.cjca.2010.12.021_bib29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2010.12.021_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","article-title":"The friction cost method for measuring indirect costs of disease","volume":"14","author":"Koopmanschap","year":"1995","journal-title":"J Health Econ"},{"key":"10.1016\/j.cjca.2010.12.021_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00019053-200321030-00004","article-title":"A meta-analysis of quality-of-life estimates for stroke","volume":"21","author":"Tengs","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cjca.2010.12.021_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/0272989X9301300210","article-title":"Stability of time-tradeoff utilities in survivors of myocardial infarction","volume":"13","author":"Tsevat","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cjca.2010.12.021_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0272989X9301300202","article-title":"The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors","volume":"13","author":"Fryback","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cjca.2010.12.021_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-142-4-200502150-00007","article-title":"A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone","volume":"142","author":"Schleinitz","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib37","first-page":"473","article-title":"How attractive does a new technology have to be to warrant adoption and utilization?","volume":"146","author":"Laupacis","year":"1992","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2010.12.021_bib38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.hjr.0000152239.28456.36","article-title":"The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study","volume":"11","author":"Lamy","year":"2004","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.cjca.2010.12.021_bib39","first-page":"1037","article-title":"Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial","volume":"23","author":"Kolm","year":"2007","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2010.12.021_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ahj.2005.02.044","article-title":"Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation","volume":"151","author":"Mahoney","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2010.12.021_bib41","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJM200206063462309","article-title":"Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease","volume":"346","author":"Gaspoz","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib42","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM200302063480616","article-title":"Aspirin, clopidogrel, or both for secondary prevention of coronary disease","volume":"348","author":"de Lemos","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjmed.2004.01.014","article-title":"Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis","volume":"116","author":"Schleinitz","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2010.12.021_bib44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/0272989X08318467","article-title":"Cost-effectiveness of clopidogrel: seeing through the smoke","volume":"28","author":"Goldman","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cjca.2010.12.021_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6963-3-7","article-title":"Cost of managing complications resulting from type 2 diabetes mellitus in Canada","volume":"3","author":"O'Brien","year":"2003","journal-title":"BMC Health Services Research"},{"key":"10.1016\/j.cjca.2010.12.021_bib46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1524-4733.2001.43017.x","article-title":"Diabetes in Canada: direct medical costs of major macrovascular complications","volume":"4","author":"O'Brien","year":"2001","journal-title":"Value Health"},{"key":"10.1016\/j.cjca.2010.12.021_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-6963-3-17","article-title":"Cost of managing an episode of relapse in multiple sclerosis in the United States","volume":"3","author":"O'Brien","year":"2003","journal-title":"BMC Health Serv Res"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X10000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X10000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:21Z","timestamp":1760106861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X10000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0828282X10000371"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2010.12.021","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2010.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}